{"analyses":[{"ciLowerLimit":"0.467","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.718","groupDescription":"All analyses based on final DBL were descriptive only with p-values reported as nominal.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.579","statisticalMethod":"Stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.5","upperLimit":"9.0","value":"8.2"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"6.2","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"PFS as assessed by IRC per RECIST 1.1 was defined as the time from randomization to the date of the first documented tumor progression, or death due to any cause, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Part 2 participants only","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 68.4 months","title":"Part 2: PFS Per IRC","type":"SECONDARY","unitOfMeasure":"months"}